Google Übersetzer
Argen-x
About
Argen-x (NASDAQ:ARGX) — investor relations, events, news, and company updates on 6ix.
Latest News
Today
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
Mar 20 2026
argenx announces Annual General Meeting of Shareholders on May 6, 2026
Mar 6 2026
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Feb 26 2026
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
Feb 26 2026
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Financials
Revenue
$4.24 B
Market Cap
$46.32 B
P/E Ratio
38.16
EPS
19.56